'How much money have you made?': Blumenthal vs Dr McCullough at COVID vaccine side effects hearing
Show more
Show less
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
24 minutes ago
- Time of India
Amitabh Kant calls Trump tariffs a ‘once-in-a-generation' chance, India's Agneepath moment to scale the tariff Deewaar
The United States has increased tariffs on Indian exports. Donald Trump cited India's trade practices and energy purchases from Russia as reasons. Amitabh Kant sees this as an opportunity for India to implement structural reforms. The tariffs, now at 50% on many goods, could affect Indian competitiveness in the US market. Tired of too many ads? Remove Ads Trump doubles tariffs on Indian goods to 50% Initial and additional tariffs take effect in August Senate bill proposes further penalties Tired of too many ads? Remove Ads Key export sectors to be affected The recent escalation in US tariffs on Indian exports has been described by Amitabh Kant , former G20 Sherpa and ex-CEO of NITI Aayog, as a significant opportunity for India to pursue structural economic reforms . Calling the development a 'once in a generation opportunity,' Mr Kant urged policymakers to fully utilise the moment for long-term transformation. 'Trump has provided us a once in a generation opportunity to take the next big leap on reforms. Crisis must be fully utilised,' he posted on X (formerly Twitter).US President Donald Trump has announced a steep increase in tariffs on Indian exports, raising them to 50% from the previously declared 25%. The move, which Mr Trump framed as a response to India's continued energy trade with Russia, has raised concerns over its impact on trade flows and several Indian 25% tariff initially announced on July 30 will take effect on August 7 at 9:30 am IST. An additional 25% levy will be implemented 21 days later, effectively doubling the tariff burden. On Truth Social, Mr Trump referred to India as a "friend" but criticised its trade policies and ongoing military and energy cooperation with Russia.'Remember, while India is our friend, we have, over the years, done relatively little business with them because their Tariffs are far too high, among the highest in the World,' Mr Trump stated. 'They have the most strenuous and obnoxious non-monetary Trade Barriers of any Country… and are Russia's largest buyer of ENERGY, along with China.'In addition to the executive action, a bill currently under consideration in the US Senate proposes a 500% tariff on imports from countries that continue buying oil from Russia and do not align with the US position on the Ukraine conflict. While the bill has not yet passed into law, it reflects growing bipartisan pressure to economically penalise nations maintaining strong trade ties with revised tariffs are expected to impact a broad range of Indian exports to the United States. Sectors facing the 50% duty include shrimps, organic chemicals, carpets, apparel, textiles, gems and jewellery, steel, aluminium, copper, machinery, and will face a 26% tariff, and petroleum products will be taxed at 6.9%. The increased tariffs are likely to raise costs for Indian exporters and reduce the competitiveness of their goods in the US market.
The Print
an hour ago
- The Print
Japan ready to compile extra budget to cushion US tariff blow, PM Ishiba says
'We will compile one if necessary, taking into account discussions with other parties,' Ishiba told parliament when asked by an opposition lawmaker whether the government would compile an extra budget that includes tax cuts. After suffering a stinging defeat in last month's upper house election, Ishiba's minority coalition is under pressure to heed opposition parties' demand to boost spending and cut Japan's sales tax. By Leika Kihara TOKYO (Reuters) -Japanese Prime Minister Shigeru Ishiba said on Monday the government is ready to compile an extra budget to cushion the economic blow from U.S. tariffs, a move that would add strain to the country's already worsening finances. If the government were to compile a stimulus package, an extra budget to fund the spending would be submitted to an extraordinary parliament session likely to be convened in September. Japan's trade deal struck with President Donald Trump last month lowers U.S. tariffs for imports of goods including its mainstay automobiles, easing the pain for the export-reliant economy. But there is no clarity on when U.S. tariffs for automobiles and auto parts will be cut to 15% from the current 25%, clouding the outlook for Japan's fragile recovery. Compiling an extra budget has become a regular practice in Japan as politicians call for increasing spending to support the economy, keeping its fiscal policy loose even as other countries rolled back crisis-mode spending after the COVID-19 pandemic. Ishiba has not commented on the possible size of an extra budget, but some analysts expect it could reach around 10 trillion yen ($67.68 billion), which would require additional debt issuance. The extra budget would come on top of a record 115.5 trillion yen budget for the current fiscal year. Of the total, 24.5% is being spent on financing debt. Such deficit funding costs will likely rise further as the Bank of Japan eyes more interest rate hikes, analysts say. With rising food costs hurting consumption, opposition parties have called for slashing or eliminating Japan's sales tax rate, which is set at 10% except for 8% for food. Ishiba, who is regarded as a fiscal hawk, has been cautious about cutting the sales tax, which funds social welfare costs for a rapidly ageing population. A flurry of big spending packages and ballooning social welfare costs for a rapidly ageing population have left Japan with a debt pile 250% the size of its economy – the highest among major economies. ($1 = 147.7500 yen) (Reporting by Leika Kihara; Editing by Jamie Freed) Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibility for its content.
Time of India
2 hours ago
- Time of India
Can you take antibiotics for COVID? WHO updates its guidelines on antibiotic usage for patients
As COVID-19 continues to evolve, so do the guidelines for how to tackle and treat it. Although the pandemic has drawn to a close, various strains are still at play and are causing infection amongst communities. After the Nimbus strain, now the Stratus strain is surging in the US, causing soar throat and hoarseness in voice in patients. Although these strains aren't fatal, many people still wonder: Can you take antibiotics for COVID? The answer, finally, is here. The latest guideline In a major update to its clinical guidelines, the World Health Organization (WHO) has advised against giving antibiotics to COVID-19 patients, even those with severe illness, if there's no clear sign of a bacterial infection. This shift in guidance comes after a new meta-analysis of studies showed that antibiotics do not improve outcomes in COVID-19 patients who don't have a bacterial infection. Overusing antibiotics without need, the WHO warns, could worsen the global problem of antimicrobial resistance. 'For patients with non-severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we recommend no empirical antibiotics,' the WHO said in its latest guidance. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Kate Middleton's Daring Outfit Took Prince William's Breath Away Crowdy Fan Undo 'For patients with severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we suggest no empirical antibiotics.' What are antibiotics? Antibiotics are medicines used to treat bacterial infections, not viral infections like COVID-19. They work by killing bacteria or stopping them from growing. Common illnesses treated with antibiotics include strep throat, urinary tract infections, and some types of pneumonia. COVID-19, however, is caused by the SARS-CoV-2 virus, not a bacterium. This means antibiotics do not treat the virus itself. Taking them unnecessarily won't help you recover faster, and it can cause serious side effects or even long-term health problems. Why the change? Since the beginning of the pandemic in 2020, both COVID-19 and the world's response to it have changed dramatically, the WHO noted. With lower infection rates, milder disease, and the removal of emergency public health measures, COVID-19 is now treated more like other illnesses in many countries. 'Notable changes to COVID-19 disease over this time have been overall reduced infection rates and reduced disease severity,' the WHO said. 'Care for patients with COVID-19 has become more integrated with usual healthcare systems.' These changes prompted the WHO to review and revise all of its existing COVID-related recommendations. As a result, the new guidelines remove outdated advice or recommendations that are now considered basic medical practice and not specific to COVID-19. Recommendation backed by new research The updated antibiotic recommendations are based on the latest data from a systematic review and meta-analysis. These studies looked at how patients fared when treated with antibiotics during COVID-19, and whether those treatments were really necessary in the absence of a bacterial infection. At the same time, there's growing urgency to tackle antimicrobial resistance, a serious global threat where overuse of antibiotics makes bacteria resistant to treatment. The WHO stressed that these new guidelines are aimed at everyone involved in COVID-19 care, from doctors and nurses to hospital administrators and health system planners. COVID-19: Still a threat, and ever-evolving While vaccines, treatments, and previous infections have helped many people build immunity, COVID-19 hasn't disappeared. The SARS-CoV-2 virus continues to infect thousands of people daily, causing avoidable sickness and death. 'The virus continues to evolve in terms of infectivity, immune escape, and disease severity,' the WHO warned. Even though many countries are no longer in emergency mode, COVID-19 still requires careful clinical management, especially for high-risk populations. The new WHO guideline aims to reflect this shifting landscape, balancing new scientific evidence with the current global health context. 'This guideline robustly and transparently addresses the changing landscape and evidence availability, and the continual development of treatment and management strategies for COVID-19,' the WHO added. To sum it up… Antibiotics should not be used in COVID-19 patients unless there is a strong suspicion of a bacterial infection. This applies to both mild and severe cases. The guidance is part of a broader update reflecting new evidence and a changing pandemic. Overuse of antibiotics can worsen antimicrobial resistance, a growing health threat worldwide. The new guidelines apply to all levels of the health system involved in COVID-19 care. Study finds antiseptic drug is as good as antibiotics for preventing recurrent Urinary Tract Infections
